Truist Financial Has Lowered Expectations for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its target price lowered by investment analysts at Truist Financial from $56.00 to $47.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price would suggest a potential upside of 33.41% from the company’s previous close.

Other research analysts also recently issued reports about the stock. William Blair reiterated an “outperform” rating on shares of Medline in a research note on Thursday, June 4th. Stifel Nicolaus cut their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday. Citigroup decreased their price target on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on Medline in a report on Thursday. Finally, BMO Capital Markets restated an “outperform” rating and set a $47.00 price objective on shares of Medline in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Medline currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

Medline Trading Up 2.1%

Shares of Medline stock opened at $35.23 on Thursday. The business’s fifty day moving average is $38.22 and its two-hundred day moving average is $41.72. The company has a quick ratio of 2.51, a current ratio of 4.33 and a debt-to-equity ratio of 0.66. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88. The firm has a market cap of $46.28 billion and a PE ratio of 110.09.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. Analysts anticipate that Medline will post 1.49 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Private Ltd Gic sold 271,994 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $35.33, for a total value of $9,609,548.02. Following the sale, the insider owned 24,992,766 shares of the company’s stock, valued at approximately $882,994,422.78. The trade was a 1.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jessi L. Corcoran bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the completion of the acquisition, the insider directly owned 5,000 shares in the company, valued at approximately $170,750. This represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 2,348,612 shares of company stock valued at $83,654,149 over the last quarter. Corporate insiders own 0.81% of the company’s stock.

Hedge Funds Weigh In On Medline

A number of hedge funds have recently modified their holdings of MDLN. Carlyle Group Inc. purchased a new stake in shares of Medline during the 4th quarter worth about $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in shares of Medline during the 4th quarter valued at about $4,179,591,000. Vanguard Group Inc. bought a new stake in shares of Medline in the 4th quarter valued at approximately $793,278,000. Morgan Stanley bought a new stake in shares of Medline in the 4th quarter valued at approximately $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline in the fourth quarter worth approximately $620,937,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.